CDKN2A and melanoma: The finding of Noonan et al. (2005) that a p16-derived peptide can kill rather than arrest melanoma cells was interesting and unexpected, based on the normal action of p16 of cell-cycle arrest and senescence, and has not been subsequently validated to our knowledge.